BG — Bunge Global S.A.

Sell-side consensus remains Buy (21 buy / 4 hold) with price targets around $140-$151.67, but sentiment is tempered: UBS trimmed its target to $115 and Zacks downgraded BG to Hold on valuation. The stock has rallied 9.54% in the last month but is still down 3.74% over three months, reflecting mixed conviction on whether Q2 2026 processing-margin strength and Viterra synergies are durable.

Revenue stepped up from roughly $11.6B-$13.5B per quarter pre-Q3 2025 to $21.9B-$24.0B thereafter, clearly driven by Viterra consolidation rather than organic growth. Underlying earnings are cyclical: EPS was $4.19 in Q4 2023, then fell to $0.48 in Q2 2024, $0.85 in Q3 2025, $0.49 in Q4 2025, and $0.35 in Q1 2026 before rebounding to $3.46 in Q2 2026. Q2 2026 operating margin of 4.5% and net margin of 2.8% are well above the TTM operating margin of 2.3%, suggesting a cyclical inflection, but grain merchandising remains weak and the TTM trend is still depressed.

As of 2026-09-13, at $122.41, BG trades at 23.8x TTM EPS of $5.153 and about 12.9x the $9.517 next-FY EPS estimate. That is rich versus its own 5-year average P/E of 10.0x on trailing numbers, but the forward multiple is only a modest premium and is below the 14x+ implied by analyst targets. P/B is 1.50 and P/S is 0.256 versus a 5-year average P/S of 0.22. I would call it fairly valued to slightly expensive: the stock already discounts a meaningful earnings recovery.

The stock is not pricing a no-growth commodity processor; it is pricing a recovery from depressed TTM EPS. If BG hits the raised FY26 guidance midpoint of about $9.50, the P/E compresses to roughly 12.9x, which is reasonable for a cyclical agribusiness with Viterra synergies. If soybean/softseed crush margins normalize or grain merchandising stays weak, the trailing P/E of 23.8x will look justified and the shares could re-rate lower. Q3 earnings are the key near-term confirmation point.

As of 2026-09-13, RSI is 59.43, positive but not overbought. The stock sits 4.53% above its 20-day SMA, 6.54% above its 50-day SMA, and 6.65% above its 200-day SMA, which is a moderate uptrend with positive momentum. However, BG is in the upper half of its 52-week $76.01-$134.87 range. Entry-timing implication: do not chase; wait for a pullback toward the 20/50-day SMA or a post-Q3 earnings confirmation.

• U.S. biofuel policy, especially EPA 100% SRE reallocation, could structurally lift domestic soybean/softseed crush demand and processing margins.
• Global crop supplies remain ample, pressuring grain merchandising margins and making commodity price direction a key swing factor.
• Ocean freight and supply-chain volatility affect global agricultural flows, working capital, and merchandising profitability.
• Interest rates and credit conditions matter: BG carries $9.426B of long-term debt with D/E of 1.054, and negative H1 2026 free cash flow can pressure financing costs.
• Glencore's post-Viterra ownership stake is an overhang that could create share-supply pressure as it reduces its position.

• Q3 2026 earnings release expected late October 2026: read-through on H2 processing margins, Viterra synergy capture, and any further guidance changes.
• EPA SRE reallocation implementation: a potentially underappreciated upside driver for domestic crush demand and earnings.
• Viterra integration: management raised its synergy target to $350M; further progress would support EPS and cash flow.
• Continued share buybacks, capital returns, and an eventual orderly reduction of Glencore's stake.

• Commodity and processing margin volatility: Q2 2026 strength may not persist if soybean/softseed crush margins normalize.
• Grain merchandising headwinds from ample global crop supplies and volatile ocean freight costs.
• Execution risk integrating Viterra; revenue and equity trends are distorted by the acquisition.
• Thin margins and weak returns: TTM net margin 1.1%, operating margin 2.3%, ROIC 2.7%, leaving little cushion.
• Balance sheet and cash flow: negative FCF in Q1 and Q2 2026 (-$877M and -$1,028M), D/E 1.054, and $9.426B long-term debt.
• Valuation: trailing P/E of 23.8x versus a 5-year average of 10.0x means the stock is not cheap if earnings disappoint.

Bunge is a cyclical agribusiness showing a real Q2 2026 earnings inflection and Viterra-driven scale, but the stock at $122.41 already reflects much of that recovery. Forward P/E near 13x is fair rather than cheap, while thin through-cycle margins, negative H1 free cash flow, and commodity volatility cap the risk/reward. I would not chase here; it is a neutral/hold, with a better entry on a pullback or clearer evidence that crush margins and synergies are sustainable.

Applied 13x to FMP's next-FY EPS estimate of $9.517. The multiple is a modest premium to BG's 5-year average P/E of 10.0x to reflect raised FY26 guidance, Viterra synergies, and biofuel tailwinds, but it is below the 14x+ implied by analyst targets given thin margins and cyclicality. 13 x $9.517 = $123.72.